why choose us

First received: August 21, 2023

Clinical Trial: Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

Study Status: Completed

Recruit Status: RECRUITING

Condition: Major Depressive Disorder

Study Type: INTERVENTIONAL


Official Title: A Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as an Adjunctive Treatment for Major Depressive Disorder (RELIGHT)

Brief Summary: A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).

Read more